KeyMed Biosciences Inc
HKEX:2162
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.45
49.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
KeyMed Biosciences Inc
Net Income (Common)
KeyMed Biosciences Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
Net Income (Common)
-¥359.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.9B
|
CAGR 3-Years
62%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
KeyMed Biosciences Inc
Glance View
In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.
See Also
What is KeyMed Biosciences Inc's Net Income (Common)?
Net Income (Common)
-359.4m
CNY
Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Net Income (Common) amounts to -359.4m CNY.
What is KeyMed Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
24%
Over the last year, the Net Income (Common) growth was -17%. The average annual Net Income (Common) growth rates for KeyMed Biosciences Inc have been 24% over the past three years .
You don't have any saved screeners yet
